Embecta (NASDAQ:EMBC) Releases FY 2025 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.700-2.900 for the period, compared to the consensus estimate of 2.270. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Embecta Stock Performance

Embecta stock opened at $20.59 on Thursday. Embecta has a 52-week low of $9.93 and a 52-week high of $20.80. The firm has a 50 day moving average price of $14.48 and a two-hundred day moving average price of $14.11. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 17.16 and a beta of 0.97.

Embecta Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th will be issued a dividend of $0.15 per share. The ex-dividend date is Friday, December 6th. This represents a $0.60 annualized dividend and a yield of 2.91%. Embecta’s payout ratio is 50.00%.

Wall Street Analysts Forecast Growth

Separately, BTIG Research upgraded shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target for the company in a report on Wednesday.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.